08:43 AM EDT, 10/10/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Thursday that its Tremfya monoclonal antibody showed "impressive results" across biologic-naive and biologic-refractory patients in both Crohn's disease and ulcerative colitis.

The drugmaker said Tremfya showed high rates of endoscopic remission in patients, which indicates a "normal appearance of intestinal mucosa."

Johnson & Johnson ( JNJ ) said the data from the phase 3 study of Tremfya showed greater endoscopic remission rates than ustekinumab in biologic-naive patients and biologic-refractory with Crohn's disease.

Another phase 3 study of the drug demonstrated greater rates of endoscopic remission compared to placebo in biologic/JAK inhibitor-naive and biologic/JAK inhibitor-refractory patients with ulcerative colitis.

Tremfya is approved by the US Food and Drug Administration to treat adults with moderately to severely active ulcerative colitis and is under review for Crohn's disease.

Price: 161.37, Change: +0.72, Percent Change: +0.45